Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Maintenance in High Risk DLBCL
NCT01965977Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01965977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965977.